On May 1, a clinical trial volunteer injected the Inactivated Vaccine of the New Coronavirus variant of the Omikejong variant in Hangzhou. Xinhua News Agency
On the afternoon of May 1, the clinical study of the inactivated vaccine of the New Coronavirus variant developed by Sinopharm Group's China Bio-Beijing Institute of Biological Products officially completed the first dose of vaccination in Hangzhou, Zhejiang Province. It is also the world's first inactivated covid-19 vaccine against the Semickon variant to enter clinical trials.
On May 1, a clinical trial volunteer injected the Inactivated Vaccine of the New Coronavirus variant of the Omikejong variant in Hangzhou. Xinhua News Agency
The clinical study of the Olympic vaccine in Shulan (Hangzhou) Hospital requires two doses, and the safety and immunogenicity of the Austrian vaccine in people aged 18 years and above who have not been vaccinated against the new crown virus vaccine will be evaluated. After this clinical study data is approved, the blank population that has not been vaccinated against COVID-19 can be directly vaccinated with the Austrian strain vaccine.
The inactivated vaccine of the Omiljung variant strain developed by Sinopharm's Beijing Institute of Biological Products on April 22. Xinhua News Agency
"Vaccine development of the Omikejung variant is very important, of course, the original vaccine is still effective, but after the development of the vaccine for the mutant strain, there may be a better immune effect." This also proves the speed of China's anti-epidemic work and China's efficiency. Li Lanjuan, an academician of the Chinese Academy of Engineering, said that she believes that through rigorous clinical research, the safety and efficacy of vaccines can be further proved to ensure the application of vaccines in the future.
Source: Xinhua News Agency
Editor of this issue: An Yanjing